Meta expanded its Ray-Ban smart glasses lineup on April 14, 2026, introducing two prescription-optimized frames , Blayzer and Scriber , priced at $499. The launch marks the first time Meta's AI glasses have been designed from the ground up to accommodate corrective lenses, targeting the estimated 166 million Americans who wear prescription eyewear. The move represents a decisive push from novelty wearable to daily-use device.
Supply constraints immediately undermined the global rollout. Meta suspended plans to expand into the UK, France, Italy, and Canada due to "unprecedented demand" and "extremely limited inventory," with US waitlists extending deep into the year. The company currently holds approximately 72% of the AI smart glasses market by units shipped, a position it appears unable to fully service even in its home market. Manufacturing partners have struggled to scale lens integration processes alongside the existing camera and audio hardware.
The prescription strategy is significant: it removes the primary friction point for mainstream adoption. Previously, users had to choose between smart glasses and vision correction. Solving that trade-off broadens the addressable market from early adopters to the full population of eyeglass wearers. For enterprise procurement teams, the supply situation signals that bulk orders will require long lead times and vendor diversification planning throughout 2026.